> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Anjeso Not Withdrawn Due to Safety/Efficacy
- URL: https://www.fdaweb.com/anjeso-not-withdrawn-due-to-safety-efficacy/
- Published: 2023-08-11T12:00:00.000Z
- Updated: 2026-09-14T18:49:52.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5155087

*Federal Register* notice: FDA has determined that Baudax Bio’s Anjeso (meloxicam) solution, 30 mg/mL, was not withdrawn from sale due to safety or effectiveness reasons. The determination will allow FDA to approve ANDAs that reference the product if all other legal and regulatory requirements are met. Anjeso is indicated for use in adults for managing moderate-to-severe pain, alone or in combination with non-nonsteroidal anti-inflammatory drug analgesics. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2023-08-11/pdf/2023-17263.pdf?ref=fdaweb.com).